MERCK & CO, INC. for MERCK & CO INC
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Consumer Issues/Safety/Products CSP
Access to over-the-counter medications (no specific legislation)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
Chemicals/Chemical Industry CHM
Pharmaceuticals in the environment (HR 5809; S 3397)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
Medicare/Medicaid MMM
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation). Implementation of the Independent Payment Advisory Board provisions of health care reform bill (H.R. 3590).
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ANNE ESPOSITO | — |
| ELI JOSEPH | — |
Budget/Appropriations BUD
Increased funding for CDC's National Immunization Program (Sec. 317 Program); increased funding for the AIDS Drug Assistance Program and for the Division of Viral Hepatitis at CDC (FY 11 Budget and Labor-Health & Human Services Appropriations bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
| JEROME MURRAY New | Legislative Director, Cong. G.K. Butterfield |
| JASON BENJAMIN VAN PELT | — |
Animals ANI
Use of antibiotics in animals (no specific legislation)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
Taxation/Internal Revenue Code TAX
Deferral of taxation of foreign earned income and transfer pricing of intangibles (no specific legislation). Renewal and expansion of the R&D tax credit (H.R. 422; S. 1203) Miscellaneous corporate tax provisions (H.R. 5893)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON BENJAMIN VAN PELT | — |
Copyright/Patent/Trademark CPT
Apportionment of damages and post-grant review of patents (S. 515; H.R. 1260). Settlement of patent litigation (S. 3677; S. 369).
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
Health Issues HCR
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization. Implementation of the Independent Payment Advisory Board provisions of health care reform bill (H.R. 3590). Reauthorization of the Prescription Drug User Fee Act (no specific bill).
| Lobbyist | Covered position, as disclosed |
|---|---|
| G LAWRENCE ATKINS | — |
| VICTORIA BLATTER | — |
| ERIN DARLING | — |
| ANNE ESPOSITO | — |
| ELI JOSEPH | — |
| JEROME MURRAY New | Legislative Director, Cong. G.K. Butterfield |
| ANGELA M STEWART | — |
| JASON BENJAMIN VAN PELT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.